KR20250070139A - 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 - Google Patents

중수소화된 jak 저해제를 이용한 탈모 장애의 치료 Download PDF

Info

Publication number
KR20250070139A
KR20250070139A KR1020257015799A KR20257015799A KR20250070139A KR 20250070139 A KR20250070139 A KR 20250070139A KR 1020257015799 A KR1020257015799 A KR 1020257015799A KR 20257015799 A KR20257015799 A KR 20257015799A KR 20250070139 A KR20250070139 A KR 20250070139A
Authority
KR
South Korea
Prior art keywords
compound
day
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257015799A
Other languages
English (en)
Korean (ko)
Inventor
아만다 티. 와그너
제임스 브이. 카셀라
필립 비. 그레이엄
버지니아 브라만
비니타 유탐싱
제나 본 헤흔
콜린 이. 해밀턴
Original Assignee
썬 파마슈티칼 인더스트리즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250070139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 썬 파마슈티칼 인더스트리즈 인코포레이티드 filed Critical 썬 파마슈티칼 인더스트리즈 인코포레이티드
Publication of KR20250070139A publication Critical patent/KR20250070139A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257015799A 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료 Pending KR20250070139A (ko)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US62/331,827 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US62/338,869 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US62/418,774 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US62/419,237 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US62/434,404 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US62/466,358 2017-03-02
US201762492758P 2017-05-01 2017-05-01
US62/492,758 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors
KR1020237019001A KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019001A Division KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Publications (1)

Publication Number Publication Date
KR20250070139A true KR20250070139A (ko) 2025-05-20

Family

ID=60203616

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257015799A Pending KR20250070139A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020237019001A Active KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020187034867A Ceased KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237019001A Active KR102810262B1 (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR1020187034867A Ceased KR20190003711A (ko) 2016-05-04 2017-05-04 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP3452039B1 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR20250070139A (enExample)
CN (1) CN109069493A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
AU2020219797B2 (en) * 2019-02-06 2025-10-16 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
EP4236956A1 (en) 2020-10-28 2023-09-06 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
AU2023265574A1 (en) 2022-05-04 2024-12-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
CA2581169A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN103370076A (zh) * 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
EA201492287A1 (ru) * 2012-06-15 2015-07-30 Консерт Фармасьютикалс, Инк. Дейтерированные производные руксолитиниба
ES2682043T3 (es) * 2012-07-30 2018-09-18 Concert Pharmaceuticals Inc. Ibrutinib deuterado
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
US10166183B2 (en) * 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors

Also Published As

Publication number Publication date
US20200222408A1 (en) 2020-07-16
CA3022519A1 (en) 2017-11-09
KR102810262B1 (ko) 2025-05-19
SI3452039T1 (sl) 2024-12-31
EP3452039B1 (en) 2024-07-03
US12076323B2 (en) 2024-09-03
PT3452039T (pt) 2024-10-07
US20190160068A1 (en) 2019-05-30
PL3452039T3 (pl) 2024-11-18
JP2019516684A (ja) 2019-06-20
WO2017192905A1 (en) 2017-11-09
JP2025026895A (ja) 2025-02-26
RS66006B1 (sr) 2024-10-31
MX388054B (es) 2025-03-19
CN109069493A (zh) 2018-12-21
JP7586868B2 (ja) 2024-11-19
EP4424367A3 (en) 2024-11-13
AU2023201112A1 (en) 2023-03-30
JP2022171838A (ja) 2022-11-11
EP3452039A4 (en) 2019-12-25
US10561659B2 (en) 2020-02-18
SMT202400389T1 (it) 2024-11-15
US20240423986A1 (en) 2024-12-26
AU2023201112B2 (en) 2025-05-08
BR112018072339A2 (pt) 2019-02-19
MX2018013347A (es) 2019-09-02
AU2017261286B2 (en) 2023-03-23
AU2017261286A1 (en) 2018-11-22
MX2021014175A (es) 2022-01-04
EP3452039A1 (en) 2019-03-13
AU2025213576A1 (en) 2025-08-21
JP7145080B2 (ja) 2022-09-30
EP4424367A2 (en) 2024-09-04
MX2023002324A (es) 2023-03-22
HUE068643T2 (hu) 2025-01-28
FI3452039T3 (fi) 2024-10-02
KR20230086814A (ko) 2023-06-15
MX2023002323A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
MX2023002321A (es) 2023-03-22
DK3452039T3 (da) 2024-10-07
ES2988629T3 (es) 2024-11-21
LT3452039T (lt) 2024-10-25
HRP20241345T1 (hr) 2024-12-20
MX2023002325A (es) 2023-03-22

Similar Documents

Publication Publication Date Title
KR102810262B1 (ko) 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
US10842792B2 (en) Deuterated baricitinib
US12285432B2 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
US20230390292A1 (en) Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
HK40112813A (en) Treatment of hair loss disorders with deuterated jak inhibitors
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors
KR20250022668A (ko) 중수소화된 jak 억제제를 이용해 치료하기 위한 투여 요법
OA21444A (en) Regimens For The Treatment Of Hair Loss Disorders With Deuterated Jak Inhibitors.

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250514

Application number text: 1020237019001

Filing date: 20230605

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250514

Comment text: Request for Examination of Application

PG1501 Laying open of application